Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.India-based Glenmark Pharmaceuticals, an emerging, research-based global pharmaceutical company, has started manufacturing samples at its new plant at Indore in central India.
Subscribe to our email newsletter
The samples will be shipped for the approval of the US FDA before it can introduce the products.
Glenmark has invested about $20m in the plant that has an initial capacity of a million tables per year meant for exports to the US and UK.
It is hoping to get a USFDA approval for the plant within a year, which will be crucial for its revenue growth from 2012 since the firm estimates it will run out of capacity in its existing manufacturing units within a year or so.
Currently, Glenmark has three plants in western India – one for the manufacturing of solids, one for semi solids and one for hormones. Its existing USFDA approved units cater to the US and UK markets presently.